Press Releases

Date	Title	Company
07-Jan-2026	Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA	Businesswire
07-Jan-2026	Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough	Businesswire
07-Jan-2026	bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation	Businesswire
07-Jan-2026	Kelonia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KLN-1010, an in vivo BCMA CAR-T Therapy for Relapsed and Refractory Multiple Myeloma	Businesswire
07-Jan-2026	Truvian Appoints Renowned Physician-Scientist and Diagnostic Innovator Dr. Michael Mina as Chief Medical and Strategy Officer	Businesswire
07-Jan-2026	Horizon3.ai Appoints Andres Botero as Chief Marketing Officer to Drive Strategic Growth and Category Leadership	Businesswire
07-Jan-2026	Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease	Businesswire
07-Jan-2026	BigHat Biosciences Partners With Lilly to Advance Machine-Learning-Enabled Biologics Discovery Through Lilly TuneLab	Businesswire
07-Jan-2026	eGenesis to Present at 44th Annual J.P. Morgan Healthcare Conference	Businesswire
07-Jan-2026	NeuraLight Reaches Key Milestone with Completion of International Multicenter Parkinson’s Clinical Trial	Businesswire
07-Jan-2026	First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)	Businesswire
07-Jan-2026	Evaluate Releases Look into Pharma Market in 2026	Evaluate
07-Jan-2026	Vygon appoints new general manager to lead UK subsidiary	Vygon
07-Jan-2026	Nuevocor Appoints Al Gianchetti as Chief Executive Officer	Businesswire
07-Jan-2026	Stylus Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference	Businesswire
07-Jan-2026	Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones	Businesswire
07-Jan-2026	Volastra Therapeutics Expands Clinical Development Program Following Encouraging KIF18A Inhibitor Data and Appoints New Chief Medical Officer to Lead Clinical Strategy	Businesswire
07-Jan-2026	SAGA Diagnostics® Presents Real-World Pathlight™ MRD Data at ASCO GI 2026	Businesswire
07-Jan-2026	EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan	Businesswire
07-Jan-2026	Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC	Businesswire